Literature DB >> 25176985

Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis.

Manoja K Brahma1, Rene C Adam1, Nina M Pollak1, Doris Jaeger1, Kathrin A Zierler1, Nadja Pöcher1, Renate Schreiber1, Matthias Romauch1, Tarek Moustafa1, Sandra Eder1, Thomas Ruelicke2, Karina Preiss-Landl1, Achim Lass1, Rudolf Zechner1, Guenter Haemmerle1.   

Abstract

Fibroblast growth factor 21 (FGF21) is a PPARα-regulated gene elucidated in the liver of PPARα-deficient mice or PPARα agonist-treated mice. Mice globally lacking adipose triglyceride lipase (ATGL) exhibit a marked defect in TG catabolism associated with impaired PPARα-activated gene expression in the heart and liver, including a drastic reduction in hepatic FGF21 mRNA expression. Here we show that FGF21 mRNA expression is markedly increased in the heart of ATGL-deficient mice accompanied by elevated expression of endoplasmic reticulum (ER) stress markers, which can be reversed by reconstitution of ATGL expression in cardiac muscle. In line with this assumption, the induction of ER stress increases FGF21 mRNA expression in H9C2 cardiomyotubes. Cardiac FGF21 expression was also induced upon fasting of healthy mice, implicating a role of FGF21 in cardiac energy metabolism. To address this question, we generated and characterized mice with cardiac-specific overexpression of FGF21 (CM-Fgf21). FGF21 was efficiently secreted from cardiomyocytes of CM-Fgf21 mice, which moderately affected cardiac TG homeostasis, indicating a role for FGF21 in cardiac energy metabolism. Together, our results show that FGF21 expression is activated upon cardiac ER stress linked to defective lipolysis and that a persistent increase in circulating FGF21 levels interferes with cardiac and whole body energy homeostasis.
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ER stress; adipose triglyceride lipase; cardiac lipid and energy metabolism

Mesh:

Substances:

Year:  2014        PMID: 25176985      PMCID: PMC4617126          DOI: 10.1194/jlr.M044784

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   6.676


  47 in total

1.  FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study.

Authors:  Anu Suomalainen; Jenni M Elo; Kirsi H Pietiläinen; Anna H Hakonen; Ksenia Sevastianova; Mari Korpela; Pirjo Isohanni; Sanna K Marjavaara; Tiina Tyni; Sari Kiuru-Enari; Helena Pihko; Niklas Darin; Katrin Õunap; Leo A J Kluijtmans; Anders Paetau; Jana Buzkova; Laurence A Bindoff; Johanna Annunen-Rasila; Johanna Uusimaa; Aila Rissanen; Hannele Yki-Järvinen; Michio Hirano; Mar Tulinius; Jan Smeitink; Henna Tyynismaa
Journal:  Lancet Neurol       Date:  2011-08-03       Impact factor: 44.182

2.  Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo.

Authors:  Ffolliott M Fisher; Jennifer L Estall; Andrew C Adams; Patrick J Antonellis; Holly A Bina; Jeffrey S Flier; Alexei Kharitonenkov; Bruce M Spiegelman; Eleftheria Maratos-Flier
Journal:  Endocrinology       Date:  2011-06-28       Impact factor: 4.736

3.  Mitochondrial myopathy induces a starvation-like response.

Authors:  Henna Tyynismaa; Christopher J Carroll; Nuno Raimundo; Sofia Ahola-Erkkilä; Tina Wenz; Heini Ruhanen; Kilian Guse; Akseli Hemminki; Katja E Peltola-Mjøsund; Valtteri Tulkki; Matej Oresic; Carlos T Moraes; Kirsi Pietiläinen; Iiris Hovatta; Anu Suomalainen
Journal:  Hum Mol Genet       Date:  2010-07-23       Impact factor: 6.150

4.  Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.

Authors:  Jing Xu; Shanaka Stanislaus; Narumol Chinookoswong; Yvonne Y Lau; Todd Hager; Jennifer Patel; Hongfei Ge; Jen Weiszmann; Shu-Chen Lu; Melissa Graham; Jim Busby; Randy Hecht; Yue-Sheng Li; Yang Li; Richard Lindberg; Murielle M Véniant
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-08-25       Impact factor: 4.310

5.  Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunction.

Authors:  Hong Wang; Urmila Sreenivasan; Da-Wei Gong; Kelly A O'Connell; Erinne R Dabkowski; Peter A Hecker; Nicoleta Ionica; Manige Konig; Anup Mahurkar; Yezhou Sun; William C Stanley; Carole Sztalryd
Journal:  J Lipid Res       Date:  2013-01-23       Impact factor: 5.922

6.  Fibroblast growth factor 21 protects against cardiac hypertrophy in mice.

Authors:  A Planavila; I Redondo; E Hondares; M Vinciguerra; C Munts; R Iglesias; L A Gabrielli; M Sitges; M Giralt; M van Bilsen; F Villarroya
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 7.  Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.

Authors:  Philippe Lefebvre; Giulia Chinetti; Jean-Charles Fruchart; Bart Staels
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

8.  FGF21 is an Akt-regulated myokine.

Authors:  Yasuhiro Izumiya; Holly A Bina; Noriyuki Ouchi; Yuichi Akasaki; Alexei Kharitonenkov; Kenneth Walsh
Journal:  FEBS Lett       Date:  2008-10-21       Impact factor: 4.124

Review 9.  FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling.

Authors:  Rudolf Zechner; Robert Zimmermann; Thomas O Eichmann; Sepp D Kohlwein; Guenter Haemmerle; Achim Lass; Frank Madeo
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

10.  Cardiac-specific overexpression of perilipin 5 provokes severe cardiac steatosis via the formation of a lipolytic barrier.

Authors:  Nina M Pollak; Martina Schweiger; Doris Jaeger; Dagmar Kolb; Manju Kumari; Renate Schreiber; Stephanie Kolleritsch; Philipp Markolin; Gernot F Grabner; Christoph Heier; Kathrin A Zierler; Thomas Rülicke; Robert Zimmermann; Achim Lass; Rudolf Zechner; Guenter Haemmerle
Journal:  J Lipid Res       Date:  2013-01-23       Impact factor: 6.676

View more
  27 in total

1.  FGF21 inhibitor suppresses the proliferation and migration of human umbilical vein endothelial cells through the eNOS/PI3K/AKT pathway.

Authors:  Yumei Li; Jiangnan Huang; Zhiyuan Jiang; Yang Jiao; Hui Wang
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 2.  Muscle as a "mediator" of systemic metabolism.

Authors:  Kedryn K Baskin; Benjamin R Winders; Eric N Olson
Journal:  Cell Metab       Date:  2015-02-03       Impact factor: 27.287

Review 3.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu
Journal:  J Nephrol       Date:  2018-11-14       Impact factor: 3.902

4.  Cardiac myocyte KLF5 regulates body weight via alteration of cardiac FGF21.

Authors:  Christine J Pol; Nina M Pollak; Michael J Jurczak; Effimia Zacharia; Iordanes Karagiannides; Ioannis D Kyriazis; Panagiotis Ntziachristos; Diego A Scerbo; Brett R Brown; Iannis Aifantis; Gerald I Shulman; Ira J Goldberg; Konstantinos Drosatos
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-04-26       Impact factor: 5.187

Review 5.  Cardiomyokines from the heart.

Authors:  Ayano Chiba; Haruko Watanabe-Takano; Takahiro Miyazaki; Naoki Mochizuki
Journal:  Cell Mol Life Sci       Date:  2017-12-13       Impact factor: 9.261

Review 6.  Potential roles of fibroblast growth factor 21 in the brain.

Authors:  Piangkwan Sa-Nguanmoo; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Metab Brain Dis       Date:  2016-01-06       Impact factor: 3.584

Review 7.  FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process.

Authors:  Antero Salminen; Anu Kauppinen; Kai Kaarniranta
Journal:  J Mol Med (Berl)       Date:  2016-09-27       Impact factor: 4.599

8.  Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle.

Authors:  Bolormaa Vandanmagsar; Jaycob D Warfel; Shawna E Wicks; Sujoy Ghosh; J Michael Salbaum; David Burk; Olga S Dubuisson; Tamra M Mendoza; Jingying Zhang; Robert C Noland; Randall L Mynatt
Journal:  Cell Rep       Date:  2016-05-12       Impact factor: 9.423

Review 9.  The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.

Authors:  Leiluo Geng; Karen S L Lam; Aimin Xu
Journal:  Nat Rev Endocrinol       Date:  2020-08-06       Impact factor: 43.330

Review 10.  Homeostatic sensing of dietary protein restriction: A case for FGF21.

Authors:  Cristal M Hill; Hans-Rudolf Berthoud; Heike Münzberg; Christopher D Morrison
Journal:  Front Neuroendocrinol       Date:  2018-06-08       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.